InventisBio (688382)2025-01-17 13:05Financial Performance - The company expects a net loss attributable to shareholders of approximately -244.36 million yuan for the fiscal year 2024, compared to a net loss of -283.98 million yuan in 2023, indicating a decrease in loss of 13.95% year-over-year[3][5]. - The projected net loss after deducting non-recurring gains and losses for 2024 is estimated at -254.24 million yuan[3]. - The company reported a net loss of -283.98 million yuan for the fiscal year 2023, with a loss per share of -0.49 yuan[5][6]. Revenue Expectations - Revenue for 2024 is expected to primarily come from technology licensing and collaboration, as the main products are still in the R&D phase and have not yet commenced commercial production and sales[7]. - The company anticipates that losses in 2024 will decrease due to the approval and sales of externally licensed products, although technology licensing and collaboration revenue will not cover all costs and expenses[8]. Research and Development - The company is maintaining a high level of R&D investment in 2024, focusing on key clinical trials for multiple products, including D-1553 and D-0502[8]. Earnings Forecast - As of the announcement date, there are no significant uncertainties that could affect the accuracy of the earnings forecast[9]. - The financial data provided is preliminary and subject to change, with the final audited figures to be disclosed in the official annual report[10].